GlycoMimetics is a late clinical-stage biotechnology company based in Gaithersburg, MD, specializing in the discovery and development of glycobiology-based therapies for cancers and inflammatory diseases. Their lead candidate, uproleselan, is currently in pivotal Phase 3 development for relapsed refractory acute myeloid leukemia (AML) and in a Phase 2/3 trial for newly diagnosed AML patients fit for chemotherapy. Uproleselan has received Breakthrough Therapy and Fast Track designations from the U.S. FDA for the treatment of adult AML patients with relapsed or refractory disease.
As a pioneer in glycobiology, GlycoMimetics utilizes their proprietary chemistry platform and extensive understanding of the role carbohydrates play in cell recognition to discover innovative medicines that aim to improve patient outcomes. The company has established significant collaborations with leading academics, governmental organizations, and pharmaceutical biotechnology companies to drive their proprietary programs forward.
Generated from the website